Pharmacologic weight loss agents (Wegovy, Zepbound, Contrave) coverage
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Medical necessity and prior authorization criteria for Wegovy (semaglutide), Zepbound (tirzepatide), Contrave (naltrexone/bupropion) and related agents for weight reduction, MACE risk reduction, OSA, and MASH for Medicaid members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial therapy — weight reduction
Covered for weight reduction when ALL of the following are met
Provide documentation of baseline and current weight/BMI; comprehensive program defined as meeting at least monthly for 6 months
Initial therapy — MACE risk reduction
Covered for MACE risk reduction with Wegovy when ALL of the following are met
Ozempic is indicated for MACE risk reduction in type 2 diabetes but does not substitute for Wegovy criteria
Initial therapy — obstructive sleep apnea
Covered for moderate to severe OSA in adults with obesity when ALL of the following are met
Provide baseline and current weight/BMI and documentation of CPAP compliance and residual symptoms
Initial therapy — MASH
Covered for Wegovy for noncirrhotic MASH when ALL of the following are met
Authorization length for Wegovy for MASH may be up to 12 months; documentation of clinical response (e.g., improvement in ALT, ELF score, or LSM) supports continuation
Continuation therapy
Continuation of therapy covered when ALL of the following are met
Provide baseline and current weight/BMI and documentation of participation in comprehensive weight program as applicable
Specific additional continuation requirements apply for MACE and OSA indications (see respective criteria)
Wegovy is not authorized for members who have progressed to stage F4 (cirrhosis). For the indication of noncirrhotic MASH (F2–F3), documentation must confirm fibrosis stage and ongoing clinical response; progression to F4 disqualifies the member from coverage for Wegovy for this indication.
Use of Wegovy, Zepbound, Contrave, or other covered agents in combination with any other GLP-1 receptor agonist or other weight‑loss agents (for example, phentermine/topiramate) is not permitted and will be considered not medically necessary. Continuation criteria also require documentation that the member is not using combination therapy with other GLP‑1 or weight‑loss medications.
Coding and Clinical Thresholds
| Wegovy 0.25mg | Wegovy subcutaneous injection strengths and dosing forms as listed |
| Wegovy 0.5mg | Wegovy subcutaneous injection strengths and dosing forms as listed |
| Wegovy 1mg | Wegovy subcutaneous injection strengths and dosing forms as listed |
| Wegovy 1.7mg | Wegovy subcutaneous injection strengths and dosing forms as listed |
| Wegovy 2.4mg | Wegovy subcutaneous injection strengths and dosing forms as listed |
| Zepbound 2.5mg/0.5ml | Zepbound pen concentrations |
| Zepbound 5mg/0.5ml | Zepbound pen concentrations |
| Zepbound 7.5mg/0.5ml | Zepbound pen concentrations |
| Zepbound 10mg/0.5ml | Zepbound pen concentrations |
| Zepbound 12.5mg/0.5ml | Zepbound pen concentrations |
Provider Actions & Requirements
Prior authorization required; standard 6 months (12 months for Wegovy for MASH)
Prior authorization is required for Wegovy, Zepbound and Contrave; initial approvals are typically for 6 months when criteria are met. For Wegovy prescribed for noncirrhotic MASH, initial authorization may be granted for 12 months when criteria are met.
Agent-specific trial duration and FDA maintenance dosing required for continuation
Continuation requests must document completion of an agent-specific trial period and that the member is on the FDA-recommended maintenance dose: 20 weeks of therapy for Wegovy or Zepbound, or 16 weeks of therapy for Contrave (Saxenda noted similarly).
Required clinical and program documentation
Provide documentation of baseline and current weight and BMI, evidence of participation in a comprehensive weight management program (monthly meetings for at least 6 months), and clinical notes documenting tolerability, diet/exercise adherence, and program tracking.
- Baseline weight and BMI and current weight and BMI
- Evidence of participation in a comprehensive weight management program meeting at least monthly for 6 months
- Clinical notes documenting medication tolerability and adherence to diet/exercise
Condition-specific evidence required for MACE and OSA indications
For MACE risk reduction and OSA indications, submit documentation that the member has established cardiovascular disease per the policy definitions or moderate-to-severe OSA (AHI ≥15 on PSG), evidence of continued treatment with reduced calorie diet and activity, and, for MACE, receipt of GDMT or documented reason not to use GDMT.
- MACE: documentation of established CVD (e.g., prior MI, prior stroke, symptomatic PAD, prior coronary revascularization) and proof of GDMT or reason GDMT not used
- OSA: documentation of moderate-to-severe OSA with AHI ≥15 on polysomnography and prior airway obstruction treatment (e.g., CPAP) with residual symptoms
Denial triggers for incomplete or nonconforming documentation
Claims may be denied if required documentation is not provided, including evidence of participation in a comprehensive weight management program, baseline and current weight/BMI, age eligibility, or condition-specific evidence (e.g., established CVD for MACE or AHI ≥15 for OSA); concurrent use of other GLP-1 receptor agonists is also a denial trigger.
- Missing documentation of comprehensive weight management program participation (monthly for 6 months)
- Missing baseline or current weight and BMI
- Failure to meet age requirements (e.g., ≥18 for Contrave/Zepbound and certain adult indications)
- Lack of condition-specific evidence for MACE or OSA (established CVD or AHI ≥15)
- Concurrent use of another GLP-1 receptor agonist or other weight-loss agents
Background
Pharmacologic agents covered under this policy include GLP‑1/GIP receptor agonists (e.g., Wegovy, Zepbound) and other weight‑loss medications (e.g., Contrave) when used for chronic weight management, adjunctive treatment for obstructive sleep apnea, MACE risk reduction with Wegovy, and treatment of noncirrhotic metabolic dysfunction‑associated steatohepatitis (MASH). Coverage requires integration with a comprehensive weight management program and condition‑specific documentation: for MACE risk reduction the requested drug must be Wegovy and the member must have documented established cardiovascular disease; for MASH the member must have noncirrhotic F2–F3 fibrosis confirmed by elastography or biopsy within the prior 6 months and not have progressed to cirrhosis.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.